<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01502969</url>
  </required_header>
  <id_info>
    <org_study_id>Rotavin-M1-2b</org_study_id>
    <nct_id>NCT01502969</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Assessment of Rotavin-M1 in Vietnamese Children</brief_title>
  <acronym>Rotavin-M1</acronym>
  <official_title>A Phase 2b Study of Rotavin-M1 Vaccine in Vietnamese Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Hygiene and Epidemiology, Vietnam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Hygiene and Epidemiology, Vietnam</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multiple-site phase 2b, randomized, placebo control study to evaluate the safety
      and immunogenicity of Rotavin-M1, produced by the Center for Research and Production of
      Vaccines and Biologicals, Vietnam.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators evaluate the vaccine schedule consisting of 2 doses of Rotavin-M1,
      10e6.3ffu/dose at 2 month interval in children in two study sites, Thanh Son- Phu Tho and
      Thai Binh city-Thai Binh provinces.

      This vaccine dose and schedule was chosen based on results from the previous dose-escalating
      study (NCT01377571).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-rotavirus IgA antibody responses 1 month after vaccination</measure>
    <time_frame>12 months</time_frame>
    <description>To assess IgA antibody responses 1 month after completing 2 doses of Rotavin-M1, 10e6.3ffu/dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RV-IgA antibody responses to Rotavin-M1 one year after 1st dose</measure>
    <time_frame>12 year</time_frame>
    <description>to assess RV-IgA antibody responses 9 months after the last dose (i.e. 12 months after the 1st dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-rotavirus IgG antibody responses 1 month after vaccination with Rotavin-M1</measure>
    <time_frame>12 months</time_frame>
    <description>to assess the anti-rotavirus IgG responses 1 month after completing 2 doses of Rotavin-M1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and reactogenicity of each doses of Rotavin-M1, 10e6.3ffu/dose</measure>
    <time_frame>12 months</time_frame>
    <description>to assess immediate reations (30 minutes) after administration of each dose of vaccine compared to placebo . To assess adverse events 30 days after each dose of vaccine and placebo, and serious adverse events 1 year after the 1st dose of vaccine and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-RV IgG antibody responses 1 year after the 1st dose</measure>
    <time_frame>12 month</time_frame>
    <description>To assess anti-RV IgG antibody responses 1 year after the 1st dose of Rotavin-M1 (9 months after the 2nd dose)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">799</enrollment>
  <condition>Diarrhea</condition>
  <condition>Fever</condition>
  <condition>Nausea</condition>
  <condition>Vomit</condition>
  <condition>Irritability</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Children receiving placebo (cell culture medium in absence of virus)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rotavirus vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rotavin-M1, 10e6.3ffu/dose, 2 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotavin-M1</intervention_name>
    <description>liquid, 10e6ffu/dose, 2 doses, 2 month interval</description>
    <arm_group_label>Rotavirus vaccine</arm_group_label>
    <other_name>KH0118</other_name>
    <other_name>POLYVAC</other_name>
    <other_name>G1P[8]</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cell culture medium in absence of virus</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        At study entry

          1. A healthy male or female, 6 to 12 weeks of age (42 days to 84 days of age).

          2. Full term gestation (&gt;=37 weeks).

          3. Birth weight of the subject should be &gt;=2.5 kg.

          4. Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          5. Did not use any dose of Rota virus vaccine.

          6. Written informed consent obtained from the parent or guardian of the subject.

        At dose 2

          1. Received dose 1.

          2. Oral informed consent obtained from the parent or guardian of the subject for
             continuing participate the study.

        Exclusion Criteria:

        At study entry

          1. Has a chronic disease (cardiovascular, liver, kidney disease).

          2. Acute disease at the time of enrolment.

          3. Administering corticosteroids (&gt; 1mg/kg/day).

          4. Received any immunosuppressive therapy within 4 week before vaccination
             (Administration of immunoglobulins and/or any blood product or corticosteroids for &gt;2
             weeks).

          5. Immunosuppressive or immunodeficient condition.

          6. Family has immunosuppressive or immunodeficient condition medical history.

          7. History of high fever convulsion.

          8. Allergic or reaction with any component of vaccine, includes anaphylactic shock with
             any antibiotic.

          9. Preterm of gestation delivery (gestation period &lt; 37 weeks).

         10. Low birth weight (&lt;2.5 kg).

         11. Fever (axillary temperature &gt;38oC) within 3 days before or on the day of vaccination.

         12. Malnutrition.

         13. Has any type of blood disorder, leukemia, or malignant tumor which can affect the bone
             marrow or lymph system.

         14. Use of any investigational or non-registered product (unlicensed drug or vaccine)
             other than the study vaccine within 30 days preceding the first dose of study vaccine,
             or planned use during the study period.

        At dose 2

          1. Acute disease at the time of 2nd dose.

          2. Administering corticosteroids (&gt; 1mg/kg/day).

          3. Received any immunosuppressive therapy within 4 week before vaccination
             (Administration of immunoglobulins and/or any blood product or corticosteroids for &gt;2
             weeks).

          4. History of allergic disease or reactions likely to be exacerbated by any component of
             the study vaccine.

          5. Fever (axillary temperature &gt;38oC) within 3 days before or on the day of vaccination.

          6. Has any type of blood disorder, leukemia, or malignant tumor which can affect the bone
             marrow or lymph system.

          7. Use of any investigational or non-registered product (unlicensed drug or vaccine)
             other than the study vaccine during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dang D Anh, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The National Institute of Hygiene and Epidemiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Preventive Medicine Center</name>
      <address>
        <city>Thanh Son</city>
        <state>Phu Tho</state>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thai Binh Preventive Medicine Center</name>
      <address>
        <city>Thai Binh</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <reference>
    <citation>Anh DD, Thiem VD, Fischer TK, Canh DG, Minh TT, Tho le H, Van Man N, Luan le T, Kilgore P, von Seidlein L, Glass RI. The burden of rotavirus diarrhea in Khanh Hoa Province, Vietnam: baseline assessment for a rotavirus vaccine trial. Pediatr Infect Dis J. 2006 Jan;25(1):37-40.</citation>
    <PMID>16395100</PMID>
  </reference>
  <reference>
    <citation>Nguyen TA, Yagyu F, Okame M, Phan TG, Trinh QD, Yan H, Hoang KT, Cao AT, Le Hoang P, Okitsu S, Ushijima H. Diversity of viruses associated with acute gastroenteritis in children hospitalized with diarrhea in Ho Chi Minh City, Vietnam. J Med Virol. 2007 May;79(5):582-90.</citation>
    <PMID>17385670</PMID>
  </reference>
  <reference>
    <citation>Ngo TC, Nguyen BM, Dang DA, Nguyen HT, Nguyen TT, Tran VN, Vu TT, Ogino M, Alam MM, Nakagomi T, Nakagomi O, Yamashiro T. Molecular epidemiology of rotavirus diarrhoea among children in Haiphong, Vietnam: the emergence of G3 rotavirus. Vaccine. 2009 Nov 20;27 Suppl 5:F75-80. doi: 10.1016/j.vaccine.2009.08.074.</citation>
    <PMID>19931725</PMID>
  </reference>
  <reference>
    <citation>Van Man N, Luan le T, Trach DD, Thanh NT, Van Tu P, Long NT, Anh DD, Fischer TK, Ivanoff B, Gentsch JR, Glass RI; Vietnam Rotavirus Surveillance Network. Epidemiological profile and burden of rotavirus diarrhea in Vietnam: 5 years of sentinel hospital surveillance, 1998-2003. J Infect Dis. 2005 Sep 1;192 Suppl 1:S127-32.</citation>
    <PMID>16088796</PMID>
  </reference>
  <reference>
    <citation>Kim SY, Goldie SJ, Salomon JA. Cost-effectiveness of Rotavirus vaccination in Vietnam. BMC Public Health. 2009 Jan 21;9:29. doi: 10.1186/1471-2458-9-29.</citation>
    <PMID>19159483</PMID>
  </reference>
  <reference>
    <citation>Luan le T, Trang NV, Phuong NM, Nguyen HT, Ngo HT, Nguyen HT, Tran HB, Dang HN, Dang AD, Gentsch JR, Wang Y, Esona MD, Glass RI, Steele AD, Kilgore PE, Nguyen MV, Jiang B, Nguyen HD. Development and characterization of candidate rotavirus vaccine strains derived from children with diarrhoea in Vietnam. Vaccine. 2009 Nov 20;27 Suppl 5:F130-8. doi: 10.1016/j.vaccine.2009.08.086.</citation>
    <PMID>19931712</PMID>
  </reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2011</study_first_submitted>
  <study_first_submitted_qc>December 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2012</study_first_posted>
  <last_update_submitted>December 30, 2011</last_update_submitted>
  <last_update_submitted_qc>December 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Hygiene and Epidemiology, Vietnam</investigator_affiliation>
    <investigator_full_name>Dang Duc Anh</investigator_full_name>
    <investigator_title>Deputy Director</investigator_title>
  </responsible_party>
  <keyword>diarrhea</keyword>
  <keyword>fever</keyword>
  <keyword>nausea</keyword>
  <keyword>vomit</keyword>
  <keyword>irritability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

